Product Information
MESALAMINE ER 0.375 GRAM CAP is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.4780 per EA under NDC 68382045219. Its NADAC has been published 262 times since Sep 29, 2021.
FDA first approved this application on Aug 12, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.375 g/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382045219
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA208954FDA Approved
8/12/2021
TE Code
AB
On Market Since
8/13/2021
Pharmacological Classes
Price Statistics
The NADAC for MESALAMINE ER 0.375 GRAM CAP has been published 262 times since Sep 29, 2021, and over the history we have for it it has declined 74.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4780 per EA |
|---|---|
| All-time high | $1.9270 (Jan 12, 2022) |
| All-time low | $0.4196 (Feb 18, 2026) |
| 52-week high | $0.4979 |
| 52-week low | $0.4196 |
| Median price | $0.7159 |
| Average price | $0.8485 |
| Largest weekly change | -38.7% (Jul 17, 2024) |
| Weeks tracked | 262 |
| Tracking since | Sep 29, 2021 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MESALAMINE ER 0.375 GRAM CAP?
The current National Average Drug Acquisition Cost (NADAC) for MESALAMINE ER 0.375 GRAM CAP, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.4780 per EA (NDC 68382045219), effective Sep 30, 2026.
How has the price of MESALAMINE ER 0.375 GRAM CAP changed over time?
Over the history we have for it, the NADAC for MESALAMINE ER 0.375 GRAM CAP has declined 74.6%. It has been tracked across 262 weekly CMS publications since Sep 29, 2021.
What are the highest and lowest recorded NADAC prices for MESALAMINE ER 0.375 GRAM CAP?
Since Sep 29, 2021, the NADAC for MESALAMINE ER 0.375 GRAM CAP has ranged from a low of $0.4196 (Feb 18, 2026) to a high of $1.9270 (Jan 12, 2022), with a median of $0.7159 per EA.
Are there cheaper alternatives to MESALAMINE ER 0.375 GRAM CAP?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as MESALAMINE ER 0.375 GRAM CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures MESALAMINE ER 0.375 GRAM CAP?
MESALAMINE ER 0.375 GRAM CAP (NDC 68382045219) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.